12 results
8-K
EX-99.1
TCRT
Alaunos Therapeutics, Inc.
14 Nov 23
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
12:00am
in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization; the Company’s exclusive focus on its
8-K
EX-99.1
kyf1de9e5gaxpdshdd
14 Aug 23
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim
4:16pm
- Prev
- 1
- Next